ESG Report 2023

1 1 PERFORMANCE HIGHLIGHTS IN 2023 Enhancing Medical Accessibility RMB million Annual R&D Investment 808 30 Products Included in the National Essential Drug List 66 Products Included in the National Medical Insurance Drug List 16 Products have Passed the Consistency Evaluation Normalizing Healthiness 1.1 Annual Performance Effective Governance Excellent Operational Management 32 Compliance and Business Ethics Training Sessions were Conducted in the Year 105 Invention, Utility Model and Design Patents 0 Data Leakage Case Responsible Supply Chain Management 100% of Suppliers Conducted Integrity Training Provided by the Group 100% of Major Collaborative Suppliers Passed Online and Offline Audits Traceability at the Source Buildling a Quality Brand 100% Response Rate to Customer Complaints 0 Case of Adverse Reactions due to Defective Drug Quality Striving for Excellence Environmental, Social and Governance Report 2023 The United Laboratories International Holdings Limited